{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:05:05Z","timestamp":1777500305840,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02401-w","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:02:16Z","timestamp":1718604136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revisiting intrathecal thiotepa: Efficacy and safety in secondary CNS malignancies"],"prefix":"10.1007","volume":"41","author":[{"given":"Trevor","family":"Jamison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emaan","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"Samarkandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riad El","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"6","key":"2401_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","volume":"13","author":"JF Deeken","year":"2007","unstructured":"Deeken JF, L\u00f6scher W. The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res. 2007;13(6):1663\u201374.","journal-title":"Clin Cancer Res"},{"key":"2401_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-98596-7","volume-title":"The golden guide to oncologic pharmacy","author":"CWP Schmidt","year":"2022","unstructured":"Schmidt CWP, Otoni KM. The golden guide to oncologic pharmacy. Cham: Springer International Publishing; 2022."},{"issue":"42","key":"2401_CR3","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar G, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312\u201328.","journal-title":"Oncotarget"},{"issue":"3","key":"2401_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/1097-0142(1955)8:3<498::AID-CNCR2820080310>3.0.CO;2-M","volume":"8","author":"H Shay","year":"1955","unstructured":"Shay H, Sun DC. Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancer. Cancer. 1955;8(3):498\u2013511.","journal-title":"Cancer"},{"issue":"5","key":"2401_CR5","first-page":"885","volume":"61","author":"PH Gutin","year":"1977","unstructured":"Gutin PH, et al. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep. 1977;61(5):885\u20137.","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"2401_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/archinte.1953.00240230028004","volume":"92","author":"H Shay","year":"1953","unstructured":"Shay H, et al. Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia. AMA Arch Intern Med. 1953;92(5):628\u201345.","journal-title":"AMA Arch Intern Med"},{"issue":"1","key":"2401_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1078155208096902","volume":"15","author":"ML de Lemos","year":"2009","unstructured":"de Lemos ML, et al. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer\u2019s solution for intrathecal administration. J Oncol Pharm Pract. 2009;15(1):45\u201352.","journal-title":"J Oncol Pharm Pract"},{"issue":"12 Pt 1","key":"2401_CR8","first-page":"6101","volume":"46","author":"JM Strong","year":"1986","unstructured":"Strong JM, et al. Pharmacokinetics of intraventricular and intravenous N, N\u2019, N\u2019\u2019-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 1986;46(12 Pt 1):6101\u20134.","journal-title":"Cancer Res"},{"issue":"6","key":"2401_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/cancers11060824","volume":"11","author":"S Triarico","year":"2019","unstructured":"Triarico S, et al. Improving the brain delivery of chemotherapeutic drugs in childhood brain tumors. Cancers. 2019;11(6):824.","journal-title":"Cancers"},{"key":"2401_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200544010-00001","volume":"44","author":"G Fleischhack","year":"2005","unstructured":"Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet. 2005;44:1\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2401_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/00043426-200205000-00011","volume":"24","author":"PG Fisher","year":"2002","unstructured":"Fisher PG, Kadan-Lottick NS, Korones DN. Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol. 2002;24(4):274\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2401_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-030-98596-7_9","volume-title":"The golden guide to oncologic pharmacy","author":"BM Gomes","year":"2022","unstructured":"Gomes BM. Intrathecal chemotherapy. In: Schmidt CWP, Otoni KM, editors. The golden guide to oncologic pharmacy. Cham: Springer International Publishing; 2022. p. 315\u201337."},{"key":"2401_CR13","unstructured":"Leslie Jensen UBMW. Methotrexate Injection. 2023. https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=912#:~:text=Reason%20for%20the%20Shortage,order%20due%20to%20increased%20demand."},{"key":"2401_CR14","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"14","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, et al. Incidence of brain metastases in patients diagnosed (1973\u20132001) in the metropolitan detroit cancer survielance system. J Clin Oncol. 2004;14:2865\u201372.","journal-title":"J Clin Oncol"},{"issue":"22","key":"2401_CR15","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/bloodadvances.2021004999","volume":"5","author":"C Ganzel","year":"2021","unstructured":"Ganzel C, et al. CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. Blood Adv. 2021;5(22):4560\u20138.","journal-title":"Blood Adv"},{"issue":"1","key":"2401_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03401.x","volume":"117","author":"AB Fasas","year":"2002","unstructured":"Fasas AB, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology, and extramedullary manifestations. Br J Hematol. 2002;117(1):103\u20138.","journal-title":"Br J Hematol"},{"issue":"2","key":"2401_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/leu.2009.264","volume":"24","author":"S Krishnan","year":"2010","unstructured":"Krishnan S, et al. Temporal changes in incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukemia treated on four consecutive Medical Research Council Trials, 1985\u20132001. Leukemia. 2010;24(2):450\u20139.","journal-title":"Leukemia"},{"issue":"17","key":"2401_CR18","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boheme","year":"2009","unstructured":"Boheme V, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896\u2013902.","journal-title":"Blood"},{"issue":"5","key":"2401_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/1097-0142(19950301)75:5<1100::AID-CNCR2820750508>3.0.CO;2-Q","volume":"75","author":"MA Hoffman","year":"1995","unstructured":"Hoffman MA, et al. Leukemic meningitis in B-cell prolymphocytic leukemia. A clinical, pathologic, and ultrastructural case study and a review of the literature. Cancer. 1995;75(5):1100\u20133.","journal-title":"Cancer"},{"issue":"5","key":"2401_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1034\/j.1399-3038.2003.00073.x","volume":"14","author":"AJ MacGinnitie","year":"2003","unstructured":"MacGinnitie AJ, et al. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003;14(5):409\u201311.","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"2401_CR21","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/bjh.17343","volume":"193","author":"A Claudel","year":"2021","unstructured":"Claudel A, et al. Thiotepa intrathecal injections for myelomatous central nervous system involvement. Br J Haematol. 2021;193(2):e9\u201312.","journal-title":"Br J Haematol"},{"issue":"4","key":"2401_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/1097-0142(197610)38:4<1471::AID-CNCR2820380404>3.0.CO;2-0","volume":"38","author":"PH Gutin","year":"1976","unstructured":"Gutin PH, et al. Intrathecal N, N\u2019, N\"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study. Cancer. 1976;38(4):1471\u20135.","journal-title":"Cancer"},{"issue":"3","key":"2401_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman SA, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11(3):561\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2401_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0277-5379(84)90188-3","volume":"20","author":"H Kantarjian","year":"1984","unstructured":"Kantarjian H, et al. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol. 1984;20(2):227\u201331.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"10","key":"2401_CR25","first-page":"5631","volume":"35","author":"CHO Kyoung-Min","year":"2015","unstructured":"Kyoung-Min CHO, et al. Salvage treatment with intracerebrospinal fluid thiotepa in patients with leptomeningeal metastasis after failure of methotrexate-based treatment. Anticancer Res. 2015;35(10):5631.","journal-title":"Anticancer Res"},{"issue":"6","key":"2401_CR26","first-page":"1079","volume":"26","author":"E Pape","year":"2012","unstructured":"Pape E, et al. Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo. 2012;26(6):1079\u201386.","journal-title":"In Vivo"},{"issue":"3","key":"2401_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-013-1244-x","volume":"115","author":"A Comte","year":"2013","unstructured":"Comte A, et al. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol. 2013;115(3):445\u201352.","journal-title":"J Neurooncol"},{"issue":"2","key":"2401_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14735\/amko2018139","volume":"32","author":"V Mikudova","year":"2019","unstructured":"Mikudova V, et al. Leptomeningeal metastasis in a breast cancer treated with two lines of intrathecal chemotherapy\u2014a case report. Klin Onkol. 2019;32(2):139\u201342.","journal-title":"Klin Onkol"},{"issue":"1","key":"2401_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","volume":"113","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun E, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neuro-Oncol. 2013;113(1):83\u201392.","journal-title":"J Neuro-Oncol"},{"issue":"9","key":"2401_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","volume":"7","author":"C Platini","year":"2006","unstructured":"Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 2006;7(9):778\u201380.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2401_CR31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/annonc\/mdp019","volume":"20","author":"C Ferrario","year":"2009","unstructured":"Ferrario C, et al. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol. 2009;20(4):792\u20135.","journal-title":"Ann Oncol"},{"issue":"2\u20133","key":"2401_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1005956925637","volume":"38","author":"LM DeAngelis","year":"1998","unstructured":"DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998;38(2\u20133):245\u201352.","journal-title":"J Neurooncol"},{"key":"2401_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","volume":"135","author":"MA Franzoi","year":"2019","unstructured":"Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019;135:85\u201394.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2401_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00001813-199502000-00004","volume":"6","author":"J Liebmann","year":"1995","unstructured":"Liebmann J, Gurtler J. Combination intraventricular therapy with thiotepa and cytarabine in meningeal carcinomatosis due to breast cancer: in vitro evidence for supra-additive cytotoxicity. Anticancer Drugs. 1995;6(1):40\u20134.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"2401_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/10428194.2020.1711902","volume":"61","author":"JM Beca","year":"2020","unstructured":"Beca JM, Raza K, Mow E, Keech J, Kouroukis CT. Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma. Leuk Lymphoma. 2020;61(5):1097\u2013107.","journal-title":"Leuk Lymphoma"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02401-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T02:37:58Z","timestamp":1719887878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02401-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2401"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02401-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"177"}}